MUMBAI, BARCELONA, ZUG, Switzerland, January 21, 2026: Global pharma major Lupin Limited  today announced a licensing and supply agreement through its subsidiary Lupin Atlantis Holdings SA  (LAHSA) with Galenicum Health, S.L.U. (Galenicum) for finished formulations of injectable  Semaglutide, a GLP-1 receptor agonist.  

As per the agreement, Galenicum will oversee development, manufacturing and supply, while Lupin  will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide  across 23 countries globally, including Canada, Europe, Southeast Asia and Latin America. Lupin is  well-positioned to expand its leadership in diabetes care and obesity beyond India with this  Semaglutide partnership.  

“Our partnership with Galenicum marks a strategic milestone in strengthening Lupin’s Semaglutide  portfolio. As diabetes continues to escalate globally and obesity emerges as a major global health  priority, Semaglutide stands out as a critical therapy. This collaboration enables us to capitalize on  worldwide growth opportunities in the expanding GLP-1 market. With our extensive commercial  presence across Canada, Europe, Southeast Asia, and Latin America we are positioned to scale access  at the right moment – further reinforcing our commitment to delivering high-quality, cost-effective  medicines and expanding access to Semaglutide for patients in these regions,” said Fabrice Egros,  President, Corporate Development, Lupin.  

Semaglutide is a generic form of glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar and  appetite. It is mainly prescribed for adults with Type 2 Diabetes, alongside diet and exercise, and is  also used for long-term weight management in adults with obesity or overweight conditions.  

“This partnership is a cornerstone of our strategy to scale high-impact volumes of Semaglutide  globally. At Galenicum, we have invested heavily in our GLP-1 development pipeline to meet the  surging demand for these life-changing therapies. Our goal is clear: to be a leader in the B2B GLP-1  space, providing our partners with the reliability, scale, competitiveness, and quality required to  transform patient care worldwide,” said Joaquim Domingo, co-founder of Galenicum.  

About Lupin 
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products  distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and  generic formulations, complex generics, biotechnology products, and active pharmaceutical  ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a  strong position in India and the U.S. across multiple therapy areas, including respiratory, 

cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s  health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with  a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health  outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing  Solutions.  

About Galenicum 
Galenicum is a global pharmaceutical company headquartered in Esplugues de Llobregat,  Barcelona, Spain, specializing in the development, manufacturing, and commercialization of generic  medicines and value-added generics. With a focus on affordability and quality, Galenicum  distributes its products across more than 70 countries worldwide, serving patients and healthcare  systems in Europe, Latin America, Asia, and Africa.  

The company maintains a diversified portfolio across key therapeutic areas, including  cardiovascular, central nervous system, pain management, and anti-infectives. Galenicum has a  particularly strong focus and significant developments in the field of diabetics, such as  groundbreaking work on GLP-1s.  

Galenicum operates a state-of-the-art manufacturing facility and dedicated R&D centers, supported  by a committed team. Galenicum is driven by the mission of providing affordable and reliable  therapeutic options to improve global patient health.  

To know more, visit www.lupin.com or follow us on LinkedIn  
https://www.linkedin.com/company/lupin  

To know more, visit www.galenicum.com or follow us on LinkedIn  
https://www.linkedin.com/company/galenicum-health  

For further information or queries, please contact  

Rajalakshmi Azariah  
Vice President & Global Head – Corporate Communications, Lupin  
rajalakshmiazariah@lupin.com 

Maria del Mar Fernández San Martín 
Chief People & Transformation Officer, Galenicum 
Mar.Fernandez@galenicum.com